http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Use of minor donors for living donor liver transplantation and associated ethical issues
황신,송기원,정동환,하태용,박길천,안철수,문덕복,이성규 대한이식학회 2021 Korean Journal of Transplantation Vol.35 No.3
Background: Living liver donation by minors is regarded as justifiable only if minors pos- sess the capacity to consent to donation and the procedure is in their best interests. This study analyzed the incidence of and reasons for living donor liver transplantation (LDLT) by minor donors in Korea, and discussed ethical issues regarding liver donation by mi- nors. Methods: The databases of the Korean Network for Organ Sharing (KONOS) and Asan Medical Center (AMC) from 2010 to 2019 were retrospectively reviewed to determine the incidence of LDLT by minor donors. Results: From 2010 to 2019, 590 (4.1%) of 14,243 liver donors in the KONOS database and 276 (7.5%) of 3,401 liver donors in the AMC database were minors. The proportions of minor donors in the KONOS and AMC databases were highest in 2012, at 4.1% and 12.6%, respectively, and lowest in 2019, at 1.1% and 3.0%, respectively. Because most LDLT re- cipients had relatively low model for end-stage liver disease scores and hepatocellular carcinoma, they were unlikely candidates for deceased-donor liver transplantation and were highly likely to drop out of LDLT if they waited for 1–2 years. The donor-recipient relationship of minor donors in the AMC database was first-degree in 256 (92.8%) and second- or third-degree in 20 (7.2%). Conclusions: Liver donation by minors is limitedly acceptable only when the minor proves informed, well‐considered, and autonomous consent to the procedure and the procedure is in the minor's best interests. We suggest that minors be allowed to donate only to first-degree family members.
황신,이승규,정동환,김기훈,하태용,송기원 한국간담췌외과학회 2009 한국간담췌외과학회지 Vol.13 No.1
Hepatitis B virus (HBV)-induced FHF fulminant hepatic failure (FHF) has been a main indication for urgent liver transplantation (LT), and these patients with hepatitis B virus (HBV)-induced FHF have a UNOS status of I. However, HBV-associated FHF has been downgraded to status IIa since late 2007 to eliminate the possibility of confusion between FHF and subacute / acute-orchronic liver failure. This current study evaluated the influence of this change of the UNOS status on organ allocation by using 4 sets of data (a single-institution study without LT cases, a singleinstitution study that included LT cases, a single-institution LT study and the nation-wide LT data). During the 12-year experience at Severance Hospital, HBV infection made up 30% of the 60 FHF patients. For the FHF patients, only 28.3% survived without LT. During the 6-year experience at Asan Medical Center, HBV infection made up 15.8% of the 114 FHF patients. Fifteen percent survived without LT, but 86% survived after LT. Only 1 out of the 14 cases of LT was deceased-donor LT. During the 2-year study on urgent LT at Asan Medical Center, there were 578 LT cases, including 520 living-donor LT and 58 deceased-donor LT. Of them, 120 patients (21.7%) had a UNOS status of I or IIa. The patients with HBV made up 17.8% of the status I patients and 80.3% of the status IIa patients. The one-year patient survival was 83.2% following living-donor LT and this was 71.1% following deceased-donor LT. For the nation-wide data for 8 years, 245 patients were allocated for a deceased-donor liver graft as status I (n=85) or IIa (n=160). Of them, 231 grafts were actually implanted. It was estimated that there is a 2.9- times difference in the probability for organ allocation between UNOS status I and IIa. In conclusion, down-grading of HBV-associated FHF from UNOS status I to status IIa would result in a significantly decreased probability to receive deceased-donor liver grafts. Therefore, it is concluded that such down-grading seems to involve unreasonable discrimination, leading to a disadvantage for patients with HBV-associated FHF. To avoid such dilemma for deceased organ allocation, Korea should consider adopting the model for end-stage liver disease (MELD).